<li>adenovirus types 4 and 7 live, oral<p>dexamethasone decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Corticosteroids may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of corticosteroid therapy.</p></li><li>afatinib<p>dexamethasone decreases levels of afatinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Increase afatinib daily dose by 10 mg as tolerated if chronic therapy with P-gp inducer required; resume previous afatinib dose 2-3 days after P-gp inducer discontinued.</p></li><li>aldesleukin<p>dexamethasone decreases effects of aldesleukin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid combination because corticosteroids can potentially diminish the antineoplastic effects of aldesleukin.</p></li><li>amisulpride<p>amisulpride, dexamethasone. pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of hypokalemia.</p></li><li>anthrax vaccine<p>dexamethasone decreases effects of anthrax vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>apremilast<p>dexamethasone will decrease the level or effect of apremilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with strong CYP inducers results in a significant decrease of systemic exposure of apremilast, which may result in loss of efficacy</p></li><li>astemizole<p>dexamethasone will decrease the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>axitinib<p>dexamethasone decreases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Selection of concomitant medication with no or minimal CYP3A4 induction potential is recommended.</p></li><li>bcg vaccine live<p>dexamethasone decreases effects of bcg vaccine live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>bedaquiline<p>dexamethasone will decrease the level or effect of bedaquiline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of bedaquiline with strong CYP3A4 inducers due to potential for decreased therapeutic effect</p></li><li>boceprevir<p>dexamethasone decreases levels of boceprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of boceprevir with CYP3A4 inducers may decrease plasma concentrations of boceprevir, which may result in loss of therapeutic effect. Therefore, this combination should be avoided if possible and used with caution if necessary.</p></li><li>bosutinib<p>dexamethasone decreases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers decreased bosutinib plasma concentration by ~85% .</p></li><li>cabozantinib<p>dexamethasone will decrease the level or effect of cabozantinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of cabozantinib with strong CYP3A4 inducers. If a strong CYP3A4 inducer is required, increase cabozantinib dose by 40 mg/day (Cometriq) or by 20 mg/day (Cabometyx). Resume previous dose 2-3 days after strong CYP3A4 inducer discontinued.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ceritinib<p>dexamethasone decreases levels of ceritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cisapride<p>dexamethasone will decrease the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cobicistat<p>dexamethasone will decrease the level or effect of cobicistat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with corticosteroids that induce CYP3A4 may result in loss of therapeutic effect and development of resistance to atazanavir or darunavir<span><br><br></span>cobicistat will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with corticosteroids that are metabolized by CYP3A, particularly for long-term use, may increase the risk for development of systemic corticosteroid effects including Cushing syndrome and adrenal suppression</p></li><li>dabigatran<p>dexamethasone will decrease the level or effect of dabigatran by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Avoid coadministration. P-gp inducers reduce systemic exposure of dabigatran</p></li><li>dabrafenib<p>dexamethasone decreases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>daclatasvir<p>dexamethasone will decrease the level or effect of daclatasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Increase dose of daclatasvir to 90 mg/day if unable to avoid coadministered with a moderate CYP3A inducer.</p></li><li>dihydroergotamine<p>dexamethasone will decrease the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>dihydroergotamine intranasal<p>dexamethasone will decrease the level or effect of dihydroergotamine intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>diphtheria &amp; tetanus toxoids<p>dexamethasone decreases effects of diphtheria &amp; tetanus toxoids by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>diphtheria &amp; tetanus toxoids/ acellular pertussis vaccine<p>dexamethasone decreases effects of diphtheria &amp; tetanus toxoids/ acellular pertussis vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>diphtheria &amp; tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine<p>dexamethasone decreases effects of diphtheria &amp; tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>dronedarone<p>dexamethasone will decrease the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>edoxaban<p>dexamethasone will decrease the level or effect of edoxaban by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Avoid coadministration of edoxaban with potent P-gp inducers</p></li><li>eliglustat<p>dexamethasone will decrease the level or effect of eliglustat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A inducers significantly decreases eliglustat exposure; coadministration not recommended</p></li><li>elvitegravir<p>dexamethasone will decrease the level or effect of elvitegravir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration with CYP3A inducers may result in decreased plasma concentrations of elvitegravir and/or a concomitantly administered protease inhibitor and lead to loss of therapeutic effect and to possible resistance</p></li><li>ergotamine<p>dexamethasone will decrease the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>dexamethasone will decrease the level or effect of erythromycin base by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>dexamethasone will decrease the level or effect of erythromycin ethylsuccinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>dexamethasone will decrease the level or effect of erythromycin lactobionate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>dexamethasone will decrease the level or effect of erythromycin stearate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ethinylestradiol<p>dexamethasone will decrease the level or effect of ethinylestradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. The efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended.</p></li><li>everolimus<p>dexamethasone will decrease the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>haemophilus influenzae type b vaccine<p>dexamethasone decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>hepatitis a vaccine inactivated<p>dexamethasone decreases effects of hepatitis a vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>hepatitis a/b vaccine<p>dexamethasone decreases effects of hepatitis a/b vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>hepatitis a/typhoid vaccine<p>dexamethasone decreases effects of hepatitis a/typhoid vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>hepatitis b vaccine<p>dexamethasone decreases effects of hepatitis b vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>human papillomavirus vaccine, bivalent<p>dexamethasone decreases effects of human papillomavirus vaccine, bivalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.</p></li><li>human papillomavirus vaccine, nonavalent<p>dexamethasone decreases effects of human papillomavirus vaccine, nonavalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.</p></li><li>human papillomavirus vaccine, quadrivalent<p>dexamethasone decreases effects of human papillomavirus vaccine, quadrivalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.</p></li><li>hydrocodone<p>dexamethasone will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>ibrutinib<p>dexamethasone decreases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.  Strong CYP3A inducers decrease ibrutinib plasma concentrations by ~10-fold.</p></li><li>idelalisib<p>dexamethasone will decrease the level or effect of idelalisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration; strong CYP3A4 inducers significantly decrease idelalisib systemic exposure<span><br><br></span>idelalisib will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates</p></li><li>influenza virus vaccine quadrivalent<p>dexamethasone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>influenza virus vaccine quadrivalent, intranasal<p>dexamethasone decreases effects of influenza virus vaccine quadrivalent, intranasal by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>influenza virus vaccine trivalent<p>dexamethasone decreases effects of influenza virus vaccine trivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>influenza virus vaccine trivalent, adjuvanted<p>dexamethasone decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ivabradine<p>dexamethasone will decrease the level or effect of ivabradine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ivabradine with moderate CYP3A4 inducers.</p></li><li>ivacaftor<p>dexamethasone decreases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with strong CYP3A4 inducers; systemic exposure of ivacaftor substantially reduced (ie, ~9-fold).<span><br><br></span>ivacaftor increases levels of dexamethasone by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.</p></li><li>ixazomib<p>dexamethasone will decrease the level or effect of ixazomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ixazomib with strong CYP3A inducers. Strong inducers have been shown to decrease ixazomib Cmax by 54% and AUC by 74%.</p></li><li>japanese encephalitis virus vaccine<p>dexamethasone decreases effects of japanese encephalitis virus vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>lovastatin<p>dexamethasone will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>macitentan<p>dexamethasone will decrease the level or effect of macitentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministering macitentan with strong CYP3A4 inducers </p></li><li>measles (rubeola) vaccine<p>dexamethasone decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>measles mumps and rubella vaccine, live<p>dexamethasone decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>measles, mumps, rubella and varicella vaccine, live<p>dexamethasone decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>meningococcal a c y and w-135 polysaccharide vaccine combined<p>dexamethasone decreases effects of meningococcal a c y and w-135 polysaccharide vaccine combined by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>netupitant/palonosetron<p>dexamethasone will decrease the level or effect of netupitant/palonosetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Netupitant is mainly metabolized by CYP3A4; avoid use in patients who are chronically using a strong CYP3A4 inducer</p></li><li>nintedanib<p>dexamethasone decreases levels of nintedanib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Avoid coadministration, particularly for P-gp inducers that are also CYP3A4 inducers; nintedanib is a substrate of P-gp and to a less extent CYP3A4.</p></li><li>olaparib<p>dexamethasone will decrease the level or effect of olaparib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with strong CYP3A4 inducers</p></li><li>osimertinib<p>dexamethasone will decrease the level or effect of osimertinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of osimertinib with strong CYP3A inducers.</p></li><li>palbociclib<p>dexamethasone will decrease the level or effect of palbociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A inducers decrease palbociclib plasma exposure by ~85%.</p></li><li>perampanel<p>dexamethasone will decrease the level or effect of perampanel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>pneumococcal vaccine 13-valent<p>dexamethasone decreases effects of pneumococcal vaccine 13-valent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>pneumococcal vaccine heptavalent<p>dexamethasone decreases effects of pneumococcal vaccine heptavalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>pneumococcal vaccine polyvalent<p>dexamethasone decreases effects of pneumococcal vaccine polyvalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>poliovirus vaccine inactivated<p>dexamethasone decreases effects of poliovirus vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>poliovirus vaccine live oral trivalent<p>dexamethasone decreases effects of poliovirus vaccine live oral trivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>ponatinib<p>dexamethasone decreases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid unless the coadministration outweighs the possible risk of ponatinib underexposure; monitor for signs of reduced efficacy.</p></li><li>quinidine<p>quinidine will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.</p></li><li>rabies vaccine<p>dexamethasone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.</p></li><li>rabies vaccine chick embryo cell derived<p>dexamethasone decreases effects of rabies vaccine chick embryo cell derived by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>ranolazine<p>dexamethasone will decrease the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ribociclib<p>dexamethasone will decrease the level or effect of ribociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of ribociclib with strong CYP3A inducers should be avoided.</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>rifampin<p>rifampin will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>rolapitant<p>dexamethasone will decrease the level or effect of rolapitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Long-term coadministration of strong CYP3A4 inducers with rolapitant may significantly decrease rolapitant efficacy.</p></li><li>romidepsin<p>dexamethasone will decrease the level or effect of romidepsin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with strong 3A4 inducers should be avoided if possible.</p></li><li>rotavirus oral vaccine, live<p>dexamethasone decreases effects of rotavirus oral vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>rubella vaccine<p>dexamethasone decreases effects of rubella vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>sertindole<p>dexamethasone will decrease the level or effect of sertindole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>sildenafil<p>dexamethasone will decrease the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels</p></li><li>silodosin<p>dexamethasone will decrease the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>simeprevir<p>dexamethasone decreases levels of simeprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may significantly decrease simeprevir plasma concentrations and result in loss of therapeutic effect.</p></li><li>simvastatin<p>dexamethasone will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>sirolimus<p>dexamethasone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>smallpox (vaccinia) vaccine, live<p>dexamethasone decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>sofosbuvir/velpatasvir<p>dexamethasone will decrease the level or effect of sofosbuvir/velpatasvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Sofosbuvir and velpatasvir are substrates of the drug transporter P-gp. Potent P-gp inducers may significantly decrease sofosbuvir and velpatasvir plasma concentrations, leading to potentially reduced therapeutic effect.<span><br><br></span>dexamethasone will decrease the level or effect of sofosbuvir/velpatasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Velpatasvir is a substrate of CYP2B6, CYP2C8, and CYP3A4. Drugs that are moderate-to-potent inducers of CYP2B6, CYP2C8, or CYP3A4 may significantly decrease velpatasvir plasma concentrations, leading to potentially reduced therapeutic effect.</p></li><li>sonidegib<p>dexamethasone will decrease the level or effect of sonidegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sonidegib with strong or moderate CYP3A4 inducers.</p></li><li>squill<p>dexamethasone increases toxicity of squill by unspecified interaction mechanism. Avoid or Use Alternate Drug.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>telaprevir<p>dexamethasone decreases levels of telaprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of telaprevir with CYP3A inducers may significantly reduce telaprevir plasma concentrations resulting in reduced efficacy.</p></li><li>terfenadine<p>dexamethasone will decrease the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>testosterone intranasal<p>testosterone intranasal, dexamethasone.
Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. 
Comment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease.</p></li><li>tetanus toxoid adsorbed or fluid<p>dexamethasone decreases effects of tetanus toxoid adsorbed or fluid by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>tick borne encephalitis vaccine<p>dexamethasone decreases effects of tick borne encephalitis vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>tofacitinib<p>dexamethasone, tofacitinib.
Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>tolvaptan<p>dexamethasone will decrease the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>trabectedin<p>dexamethasone will decrease the level or effect of trabectedin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>travelers diarrhea and cholera vaccine inactivated<p>dexamethasone decreases effects of travelers diarrhea and cholera vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>typhoid polysaccharide vaccine<p>dexamethasone decreases effects of typhoid polysaccharide vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>typhoid vaccine live<p>dexamethasone decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>ulipristal<p>dexamethasone will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>varicella virus vaccine live<p>dexamethasone decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>vemurafenib<p>dexamethasone decreases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>venetoclax<p>dexamethasone will decrease the level or effect of venetoclax by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of venetoclax with strong or moderate CYP3A inducers. Consider alternative treatment with agents that have less CYP3A induction.</p></li><li>vorapaxar<p>dexamethasone decreases levels of vorapaxar by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>yellow fever vaccine<p>dexamethasone decreases effects of yellow fever vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li><li>zoster vaccine live<p>dexamethasone decreases effects of zoster vaccine live by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.</p></li>